Thus, the development of PTBP1 inhibitors has a potential synergistic effect on reducing tumour resistance to targeted drugs, yet these studies represent another major gap in the field of gastric cancer, and our study attempts to break through the limitations of PTBP1 in the therapeutic field of gastric cancer. Here, PTBP1 is linked to gastric cancer.